Related Experiment Videos
Ciprofloxacin in neonatal Enterobacter cloacae septicaemia
M J Bannon1, P R Stutchfield, A M Weindling
1Department of Child Health, Liverpool Maternity Hospital.
Insights
Intravenous ciprofloxacin effectively eradicated multiresistant Enterobacter cloacae infections in premature infants without inducing bacterial resistance or causing side effects. This treatment achieved adequate drug concentrations in all patients.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Multiresistant Enterobacter cloacae poses a significant threat to vulnerable premature infants.
- Limited effective treatment options exist for these infections.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous ciprofloxacin in treating multiresistant Enterobacter cloacae infections in premature infants.
Main Methods:
- Six premature infants with confirmed multiresistant Enterobacter cloacae infection received intravenous ciprofloxacin at a dosage of 10 mg/kg/day.
- Bacterial eradication, development of resistance, plasma drug concentrations, and clinical side effects were monitored.
Main Results:
- Eradication of infection was achieved in all six treated infants.
- No bacterial resistance to ciprofloxacin developed during the treatment course.
- Adequate plasma ciprofloxacin concentrations were achieved in all patients.
- No clinical evidence of adverse side effects was observed.
Conclusions:
- Intravenous ciprofloxacin is a safe and effective treatment for multiresistant Enterobacter cloacae infections in premature infants.
- The drug demonstrated favorable pharmacokinetic properties and did not induce resistance in this patient population.
Abstract:
Multiresistant Enterobacter cloacae infection in six premature infants was eradicated with intravenous ciprofloxacin (10 mg/kg/day). Bacterial resistance did not develop. Adequate plasma ciprofloxacin concentrations were achieved in all treated patients. No clinical evidence of side effects was observed.